The complaint centers on a period between January 14, 2025, and May 6, 2026, during which Zoetis allegedly obscured critical headwinds facing its portfolio. According to the filing, the company failed to disclose that demand for its canine pain treatment, Librela, stalled following FDA safety alerts regarding potential neurological side effects. Furthermore, the suit claims Zoetis did not adequately report that its parasiticide, Simparica Trio, was hemorrhaging market share to lower-priced competitors.
In section Releases
Investors Eye Lead Role in Zoetis Securities Fraud Suit
Investors who sustained financial losses tied to Zoetis Inc. stock now have until July 27, 2026, to seek lead plaintiff status in a securities fraud class action. The litigation, spearheaded by Glancy Prongay & Murray LLP, targets alleged misrepresentations regarding the company’s flagship veterinary product performance and market positioning.
Beyond these specific product struggles, the lawsuit asserts that the company’s dermatology offerings—Apoquel and Cytopoint—faced significant erosion from new market entrants. The legal action alleges that these omissions rendered the company's public statements regarding its business health materially misleading. Investors looking to participate or obtain more information regarding their legal standing can contact attorney Charles Linehan at Glancy Prongay & Murray LLP in Los Angeles.
Comments (0)
No comments yet. Be the first!